English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tyrosine kinase inhibitors have significantly improved outcomes for non-small cell lung cancer patient. However, notwithstanding the favorable clinical effects, preclinical toxicity and clinical adverse effects (AEs) inevitably appeared. The impact on safety and degree of toxicity of these promising therapies is not well characterized in patients only with targeted therapy without any chemoor radiotherapy. We report a case of a non-small cell lung cancer patient who was treated a series of tyrosine kinase inhibitors, including gefitinib, osimertinib, cabozantinib and anlotinib. However, the patient progressively developed into an explosive interstitial pneumonia and died. It is therefore necessary to monitor non-small cell lung cancer patients with tyrosine kinase inhibitors or with pre-existing interstitial lung disease (ILD) very closely as they are at high risk of developing fatal interstitial lung disease.

translational cancer research

Fatal interstitial lung disease associated with a series of tyrosine kinase inhibitors treatment in a non-small cell lung cancer patient: a case report